Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • Posters & Publications
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 15, 2018 8:01am EDT

Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

Sep 25, 2018 8:00am EDT

Matinas BioPharma to Present at the MicroCap Conference

Sep 06, 2018 8:01am EDT

Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors

Sep 05, 2018 8:00am EDT

Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

Aug 16, 2018 8:00am EDT

Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop

Aug 10, 2018 8:15am EDT

Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Jul 09, 2018 9:15am EDT

NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology

Jun 22, 2018 8:30am EDT

Matinas BioPharma Announces Closing of $8.0 Million Public Offering

Jun 19, 2018 8:00am EDT

Matinas BioPharma Announces Pricing of $8.0 Million Public Offering

Jun 12, 2018 8:00am EDT

Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host

RSS
  • Prev
    • 1...
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • ...28
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • Posters & Publications

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2025 Matinas BioPharma Holdings, Inc. All Rights Reserved.